Squamous Cell Carcinoma — SCE Dermatology MCQ

Correct answer: E — Switch Ciclosporin to Sirolimus

The correct answer is E, switch Ciclosporin to Sirolimus. Calcineurin inhibitors such as ciclosporin directly promote keratinocyte carcinogenesis and impair tumour surveillance, whereas mTOR inhibitors (sirolimus, everolimus) have intrinsic antiproliferative and antitumour activity through inhibition of the PI3K/AKT/mTOR pathway. Randomised trial and cohort evidence in renal transplant recipients with multiple non-melanoma skin cancers shows that converting from a calcineurin inhibitor to sirolimus significantly reduces new squamous cell carcinoma and Bowen's disease occurrence, with a markedly longer time to new lesion development compared with remaining on calcineurin-based regimens. Given this patient's multiple biopsy-proven in-situ SCCs on a ciclosporin-based regimen, a class switch to an mTOR inhibitor is the single most effective long-term strategy to reduce future skin cancer risk, and this is supported by UK transplant dermatology practice. Why the other options are wrong: A. Topical 5-fluorouracil to all lesions: this treats existing field change and in-situ lesions but has no systemic effect on the underlying immunosuppression-driven carcinogenic process, so new lesions will keep arising elsewhere. B. Start oral Acitretin: retinoids can be used as chemopreventive adjuncts in transplant recipients with a very high skin cancer burden, but they are less effective than an immunosuppression class switch and are limited by teratogenicity, hyperlipidaemia and poor long-term tolerability. D. Reduce overall immunosuppression dose: dose reduction alone lowers cumulative immunosuppressive burden but does not remove the specifically pro-carcinogenic calcineurin inhibitor effect, and carries graft rejection risk without the added antitumour benefit that mTOR inhibition provides. C. Increase sun protection advice: UV avoidance is essential baseline care but is a modifiable environmental factor only, and alone will not counteract the pharmacological carcinogenic drive of continued calcineurin inhibitor therapy. Key point: In transplant recipients developing multiple keratinocyte skin cancers on a calcineurin inhibitor, switching to an mTOR inhibitor (sirolimus/everolimus) is the single most effective long-term measure because it directly reverses the drug-driven carcinogenic mechanism rather than just treating lesions or reducing overall drug load.

Reference: British Journal of Dermatology / PubMed: Alter M et al, 'Non-melanoma skin cancer is reduced after switch of immunosuppression to mTOR-inhibitors in organ transplant recipients', J Dtsch Dermatol Ges 2014 (PMID 24813579); consistent with BAD guidance on management of transplant-associated skin cancer, https://pubmed.ncbi.nlm.nih.gov/24813579/